HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starpharma’s COVID Nasal Spray Launched In UK

Executive Summary

Australia's Starpharma has launched in the UK its Viraleze antiviral COVID-19 nasal spray. On pack messaging states that the product "inactivates respiratory viruses, including >99.9% of coronavirus SARS-CoV-2."

You may also be interested in...



Australia’s Starpharma Plans To Launch COVID-Killing Nasal Spray In Europe

Starpharma's COVID-busting Viraleze antiviral nasal spray will soon be available across Europe, included the UK. But will it fall foul of local evidence requirements, for example in France, where the country's medicines agency has halted the sale of Pharma & Beauty (P&B) Group's COV-Defense spray until its efficacy against COVID has been confirmed by human-based studies?

France Puts The Brakes On Launch Of Anti-COVID Nasal Spray

COV-Defense nasal spray, claimed to inactivate the SARS-CoV-2 virus, will no longer launch in France after regulator ANSM demanded rigorous efficacy and safety data.

UK Researchers Seek Commercial Partner For Nasal Spray Shown To ‘Prevent’ COVID-19

A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.

Topics

UsernamePublicRestriction

Register

RS151177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel